AR087471A1 - Metodos de tratamiento de enfermedades degenerativas de la retina - Google Patents
Metodos de tratamiento de enfermedades degenerativas de la retinaInfo
- Publication number
- AR087471A1 AR087471A1 ARP120102872A ARP120102872A AR087471A1 AR 087471 A1 AR087471 A1 AR 087471A1 AR P120102872 A ARP120102872 A AR P120102872A AR P120102872 A ARP120102872 A AR P120102872A AR 087471 A1 AR087471 A1 AR 087471A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- group
- wnt
- stem cell
- combination
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000003412 degenerative effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 210000001525 retina Anatomy 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 9
- 230000019491 signal transduction Effects 0.000 abstract 6
- 210000000130 stem cell Anatomy 0.000 abstract 5
- 201000007737 Retinal degeneration Diseases 0.000 abstract 3
- 208000002780 macular degeneration Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000004258 retinal degeneration Effects 0.000 abstract 3
- 239000012190 activator Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 208000033810 Choroidal dystrophy Diseases 0.000 abstract 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 abstract 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 abstract 1
- 208000035719 Maculopathy Diseases 0.000 abstract 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 abstract 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 abstract 1
- 208000027073 Stargardt disease Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 abstract 1
- 208000003571 choroideremia Diseases 0.000 abstract 1
- 208000006623 congenital stationary night blindness Diseases 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176713A EP2554662A1 (en) | 2011-08-05 | 2011-08-05 | Methods of treatment of retinal degeneration diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087471A1 true AR087471A1 (es) | 2014-03-26 |
Family
ID=46826437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102872A AR087471A1 (es) | 2011-08-05 | 2012-08-06 | Metodos de tratamiento de enfermedades degenerativas de la retina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140199277A1 (enExample) |
| EP (2) | EP2554662A1 (enExample) |
| JP (1) | JP2014527407A (enExample) |
| KR (1) | KR20140068936A (enExample) |
| CN (1) | CN104011203A (enExample) |
| AR (1) | AR087471A1 (enExample) |
| AU (1) | AU2012293681A1 (enExample) |
| BR (1) | BR112014002718A8 (enExample) |
| CA (1) | CA2844106A1 (enExample) |
| CO (1) | CO7081142A2 (enExample) |
| IL (1) | IL230830A0 (enExample) |
| MX (1) | MX2014001475A (enExample) |
| RU (1) | RU2014108478A (enExample) |
| SG (1) | SG2014008080A (enExample) |
| WO (1) | WO2013020945A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012314330B2 (en) * | 2011-09-29 | 2017-08-24 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods for the treatment of degenerative retinal conditions |
| SG11201605833PA (en) | 2014-01-17 | 2016-08-30 | Sumitomo Chemical Co | Method for manufacturing ciliary margin stem cells |
| KR102612871B1 (ko) * | 2014-09-16 | 2023-12-13 | 젠자임 코포레이션 | 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터 |
| RU2578526C1 (ru) * | 2014-12-25 | 2016-03-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа |
| RU2569481C1 (ru) * | 2014-12-25 | 2015-11-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа |
| KR101779932B1 (ko) * | 2015-09-15 | 2017-09-21 | 주식회사 스템랩 | 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| KR101674622B1 (ko) * | 2016-07-07 | 2016-11-09 | 국민대학교산학협력단 | 세스퀴테르펜 유도체의 신규한 용도 |
| CA3032153A1 (en) * | 2016-08-19 | 2018-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
| WO2018106369A2 (en) * | 2016-11-06 | 2018-06-14 | Nanoscope Technologies Llc | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof |
| EP3616120B1 (en) | 2017-04-27 | 2024-09-04 | Retinascan Limited | System and method for automated funduscopic image analysis |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2018210994A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| US20210139844A1 (en) * | 2017-06-15 | 2021-05-13 | University Of North Texas Health Science Center | Reprogramming fibroblasts to retinal cells |
| EP3668487A4 (en) * | 2017-08-20 | 2020-08-26 | The Regents of the University of California | MODULATION OF WNT5A TO TREAT GLAUCOMA |
| EP3773638A4 (en) * | 2018-04-06 | 2022-04-06 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR TREATING LOSS OF VISION BY GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS |
| EP3937955A4 (en) * | 2019-03-15 | 2022-12-07 | The Schepens Eye Research Institute, Inc. | ISOLATION, ENHANCEMENT AND EXPANSION OF CONICAL PROGENITOR CELLS AND THEIR USES |
| CN110706164A (zh) * | 2019-09-03 | 2020-01-17 | 北京爱博同心医学科技有限公司 | 基于增强现实的管状视野图像变形显示方法及眼镜 |
| US20230034053A1 (en) * | 2019-09-25 | 2023-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Metabolic rescue of retinal degeneration |
| KR20210119766A (ko) * | 2020-03-25 | 2021-10-06 | 서울대학교병원 | 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물 |
| KR102655748B1 (ko) * | 2023-06-08 | 2024-04-05 | 충북대학교 산학협력단 | 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법 |
| KR102655735B1 (ko) * | 2023-06-09 | 2024-04-05 | 충북대학교 산학협력단 | 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포 |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6128654A (en) | 1997-02-14 | 2000-10-03 | Advanced Micro Devices, Inc. | Method and apparatus for transmitting multiple copies by replicating data identifiers |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | グリコーゲンシンターゼキナーゼ３のインヒビター |
| AU784748B2 (en) | 1999-12-17 | 2006-06-08 | Novartis Vaccines And Diagnostics, Inc. | Bicyclic inhibitors of glycogen synthase kinase 3 |
| ATE384704T1 (de) | 1999-12-17 | 2008-02-15 | Novartis Vaccines & Diagnostic | Pyrazin-basierte hemmer der glycogen-synthase- kinase 3 |
| CN100506801C (zh) | 2000-09-06 | 2009-07-01 | 诺华疫苗和诊断公司 | 糖元合成酶激酶3的抑制剂 |
| ES2302106T3 (es) | 2000-09-11 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina. |
| JP4523271B2 (ja) | 2001-06-01 | 2010-08-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール化合物 |
| JP4656838B2 (ja) | 2002-02-06 | 2011-03-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
| JP2005525362A (ja) | 2002-03-01 | 2005-08-25 | カイロン コーポレイション | 虚血の処置のための方法および組成物 |
| US20050129665A1 (en) | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| US7838290B2 (en) * | 2002-07-25 | 2010-11-23 | The Scripps Research Institute | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
| DE60333762D1 (de) | 2002-08-23 | 2010-09-23 | Novartis Vaccines & Diagnostic | Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren |
| JP2006506383A (ja) | 2002-10-21 | 2006-02-23 | カイロン コーポレイション | グリコーゲンシンターゼキナーゼ３のインヒビター |
| EP1624758A4 (en) * | 2003-05-02 | 2007-03-07 | Scripps Research Inst | HEMOPOETIC STEM CELLS AND METHOD FOR THE TREATMENT OF EYE-RELATED VASCULAR DISEASES USING THESE STEM CELLS |
| KR20060056377A (ko) | 2003-08-13 | 2006-05-24 | 카이론 코포레이션 | Ｇｓｋ-3 억제제 및 그것의 사용 |
| JP2008512376A (ja) * | 2004-09-03 | 2008-04-24 | ザ・スクリプス・リサーチ・インステイチユート | 単離された系統陰性造血幹細胞及びこれを用いた治療方法 |
| US7850960B2 (en) * | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| JP5173442B2 (ja) | 2005-02-24 | 2013-04-03 | ザ スクリプス リサーチ インスティチュート | 未熟児網膜症及び関連網膜症疾患の治療のための方法 |
| US20070231306A1 (en) * | 2005-02-24 | 2007-10-04 | The Scripps Research Institute | Isolated myeloid-like cell populations and methods of treatment therewith |
| CA2613889A1 (en) * | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
| EA201070022A1 (ru) * | 2007-06-15 | 2010-06-30 | Гарнет Байотерапьютикс Инк. | Лечение заболеваний и нарушений с использованием самообновляющихся образующих колонии клеток, культивированных и размноженных in vitro |
| EP2090649A1 (en) | 2008-02-13 | 2009-08-19 | Fondazione Telethon | Method for reprogramming differentiated cells |
| GB0816577D0 (en) * | 2008-09-11 | 2008-10-15 | Axordia Ltd | Growth factor |
| EP2486126B1 (en) * | 2009-10-06 | 2017-12-06 | SNU R & DB Foundation | Method for differentiation into retinal cells from stem cells |
-
2011
- 2011-08-05 EP EP11176713A patent/EP2554662A1/en not_active Withdrawn
-
2012
- 2012-08-06 KR KR1020147006060A patent/KR20140068936A/ko not_active Withdrawn
- 2012-08-06 SG SG2014008080A patent/SG2014008080A/en unknown
- 2012-08-06 US US14/237,297 patent/US20140199277A1/en not_active Abandoned
- 2012-08-06 MX MX2014001475A patent/MX2014001475A/es not_active Application Discontinuation
- 2012-08-06 AU AU2012293681A patent/AU2012293681A1/en not_active Abandoned
- 2012-08-06 EP EP12756386.4A patent/EP2739723A1/en not_active Withdrawn
- 2012-08-06 AR ARP120102872A patent/AR087471A1/es unknown
- 2012-08-06 JP JP2014523346A patent/JP2014527407A/ja active Pending
- 2012-08-06 BR BR112014002718A patent/BR112014002718A8/pt not_active IP Right Cessation
- 2012-08-06 WO PCT/EP2012/065327 patent/WO2013020945A1/en not_active Ceased
- 2012-08-06 CN CN201280049453.2A patent/CN104011203A/zh active Pending
- 2012-08-06 CA CA2844106A patent/CA2844106A1/en not_active Abandoned
- 2012-08-06 RU RU2014108478/10A patent/RU2014108478A/ru not_active Application Discontinuation
-
2014
- 2014-02-05 IL IL230830A patent/IL230830A0/en unknown
- 2014-03-05 CO CO14047158A patent/CO7081142A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104011203A (zh) | 2014-08-27 |
| EP2739723A1 (en) | 2014-06-11 |
| US20140199277A1 (en) | 2014-07-17 |
| RU2014108478A (ru) | 2015-09-10 |
| JP2014527407A (ja) | 2014-10-16 |
| WO2013020945A1 (en) | 2013-02-14 |
| AU2012293681A1 (en) | 2014-03-06 |
| NZ621345A (en) | 2015-09-25 |
| CA2844106A1 (en) | 2013-02-14 |
| IL230830A0 (en) | 2014-03-31 |
| MX2014001475A (es) | 2014-07-22 |
| CO7081142A2 (es) | 2014-10-10 |
| BR112014002718A2 (pt) | 2017-06-13 |
| SG2014008080A (en) | 2014-03-28 |
| WO2013020945A9 (en) | 2013-04-04 |
| EP2554662A1 (en) | 2013-02-06 |
| BR112014002718A8 (pt) | 2017-06-20 |
| KR20140068936A (ko) | 2014-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087471A1 (es) | Metodos de tratamiento de enfermedades degenerativas de la retina | |
| BR112014018524A2 (pt) | derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits | |
| CU20110096A7 (es) | Compuestos que expanden las células madre hematopoyéticas | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| EP4606890A3 (en) | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX2018009257A (es) | Derivados de benzimidazol como moduladores de ror-gamma. | |
| MX2019010171A (es) | Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular. | |
| CL2014000363A1 (es) | Compuestos derivados de 1,2,5-oxadiazoles, inhibidores de indolamina 2,3-dioxigenasa; composicion farmaceutica; proceso para prepararlos; y su uso para el tratamiento de cancer, infeccion viral, depresion, desorden neurodegenerativo, trauma, cataratas, rechazo de transplante de un organo, enfermedades autoinmunes, entre otros. | |
| GT201200242A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| CL2008001620A1 (es) | Induccion de fenotipo tolerogenico en celulas dendriticas maduras | |
| CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
| CO7240407A2 (es) | Formas cristalinas de un modulador del receptor androgénico | |
| JP2014527407A5 (enExample) | ||
| MX377796B (es) | Compuestos y composiciones para inducir condrogenesis. | |
| MX366968B (es) | Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo. | |
| AR098693A1 (es) | Método para producir células del epitelio pigmentario retiniano (rpe) | |
| ECSP16074478A (es) | Compuestos novedosos | |
| CU20170153A7 (es) | Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| AR100306A1 (es) | Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia | |
| MX2022003039A (es) | Metodo de seleccion de donantes universales para identificar donantes de celulas nk. | |
| AR102779A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| AR086800A1 (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib | |
| CL2012002612A1 (es) | Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |